, /PRNewswire/ -- Charles &Â Colvard, Ltd. (OTC: CTHR) (the "Company"), a globally recognized fine jewelry company that specializes in moissanite and lab-grown diamonds, today announced plans to expand its lab-grown diamond ("LGD") offerings to consumers as well as wholesale markets with the supply chain support from its strategic investor, Ethara Capital ("Ethara"), whose affiliates pioneered Chemical Vapor Deposition LGD manufacturing, and own and operate over 3,000 diamond-growing machines today. Forward ...

Expanding over 600,000 square feet of active projects and strengthening the Company’s Construction DivisionAUSTIN, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – Golden Triangle Ventures, Inc. (OTC: GTVH), a diversified holding company focused on building and scaling high-growth operating businesses, today announced the acquisition of Deep South Electrical Contractors, a Texas-based industry leader generating between $6 million and $7 million in annual revenue and on track to surpass $10 million in 2026 ...

Following some strategic acquisitions during the past year, this mortgage company looks like an attractive investment opportunity.Rocket Companies (RKT -2.99%) has been a roller coaster ride since its initial public offering (IPO) on the stock market in 2020. After rising as high as $43 per share in March 2021, Rocket's journey went into reverse in 2022 as rising interest rates contributed to a slowdown in the housing market.At one point, the stock plummeted as low as $6 per share. However, there has been a ...

Automotive Industry Performance - Several automotive stocks are outperforming the S&P 500 in 2025, with General Motors up 14.5%, Ford up 20.45%, and Tesla up over 37% in the last three months [1][2] Consumer Behavior and Market Trends - In Q2 2025, consumers accelerated vehicle purchases due to tariff concerns on imported parts, while in Q3, electric vehicle buyers rushed to purchase before EV tax incentives ended on October 1 [2] - There are concerns that auto sales may disappoint in Q4, but the Federal Reserve's potential long-term rate-cutting cycle may lead to attractive year-end deals for consumers [2] Company Strategies - General Motors is focusing on both internal combustion engine vehicles and electric vehicles, with a 43% increase in EV sales in the last quarter, significantly outpacing the industry's 11% growth [4][5] - GM plans to reintroduce plug-in hybrid models in 2027 to capture market share in the truck and SUV categories [5] - Ford is expanding its hybrid lineup, expecting hybrid sales to surpass EV sales in the U.S. in the coming years, while still investing heavily in EV infrastructure [7][10] - Tesla remains a leader in the EV space, benefiting from vertical integration and expansion into European markets, with a focus on autonomous driving as a long-term growth driver [12][13] Stock Valuation and Analyst Insights - GM stock is trading near its 52-week high, with analysts raising price targets, including UBS increasing its target from $56 to $81 [6] - Ford's stock is supported by its made-in-the-USA footprint and strong F-Series sales, alongside a dividend yield above 4% [10] - Tesla's stock is characterized by volatility, but its long-term potential is bolstered by its software-driven revenue streams [12][13]

Core Viewpoint - Vivakor, Inc. has signed a term sheet to secure up to $23 million in funding through the issuance of a new series of convertible preferred stock, aimed at accelerating growth in its crude oil marketing and remediation businesses while enhancing integration across its transportation operations in key oil basins [2][3]. Funding and Financial Structure - The proposed transaction includes the issuance of $25 million in Series B Convertible Preferred Stock, which will be convertible into common stock at a maximum price of $0.75 per share after one year [5]. - Vivakor's marketing segment is set to receive $15 million in restricted cash to establish a credit facility for crude oil marketing, alongside $3 million in unrestricted working capital for operational needs [4]. - The remediation segment will gain at least $5 million in assets, including land, equipment, and crude oil inventory [4]. Operational Enhancements - The counterparty will exclusively use Vivakor's trucking fleet for three years in the Permian and Eagle Ford Basins, which is expected to increase utilization and throughput across the transportation network [5]. - The transaction is anticipated to create synergies across all operating divisions, enhancing crude oil injection and terminaling services [4]. Strategic Goals - The transaction is designed to support the expansion of Vivakor's crude oil marketing and remediation segments, driving additional volumes across its trucking fleet and creating immediate revenue opportunities [3][4]. - The company aims for deeper vertical integration across its platform, leveraging the new capital and assets to enhance crude oil throughput and remediation capabilities [5].

▼ MALIBU BOATS, INC." Leading the Future of Marine INVESTOR DAY September 2025 Forward Looking Statements This presentation includes froward-looking statements (as such term is defined in the Pivate Securities Litigation Reform Act of 1995). Forward-looking statements can be i and phrases as "believes," "anticipates," "oкpects," "ntends," "will," "should," continue" and similar expressions, comparable terminology or the negative thereof, and inc statements in this presentation regardingt future events, pote ...

Core Insights - PharmAGRI Capital Partners is targeting a $10 billion total addressable market (TAM) in federal procurement of plant-based prescription drugs currently sourced from foreign manufacturers, aiming to enhance domestic production and compliance [1][8] - The company’s strategy emphasizes control over drug sourcing, leveraging a vertically integrated "seed to prescription drug" model that aligns with federal contract obligations [2][9] - Following the merger with Bright Green Corporation, PharmAGRI is positioned for relisting on Nasdaq, absorbing critical assets and ensuring shareholder liquidity without lock-up restrictions [3][4][8] Group 1: Market Opportunity and Strategy - The $10 billion TAM represents a significant opportunity for PharmAGRI to provide a sovereign alternative to foreign-sourced drugs, focusing on compliance and domestic manufacturing [1][8] - The company plans to utilize Tesla robotics to automate operations, enhancing efficiency and compliance in drug production [2][9] - PharmAGRI is also exploring acquisitions of offshore companies with advanced manufacturing capabilities to bolster its production capacity while maintaining regulatory compliance [9] Group 2: Merger and Corporate Structure - The merger with Bright Green Corporation will result in the latter merging out of existence, with its assets and registrations absorbed by PharmAGRI, facilitating a smoother relisting process [4][6] - Under the leadership of Lynn Stockwell, the company has undergone significant restructuring to consolidate assets and improve operational efficiency [5][6] - The merger is being executed under a court-supervised restructuring plan, ensuring procedural integrity and strategic continuity [6] Group 3: Leadership and Governance - Lynn Stockwell has taken full control of PharmAGRI, implementing changes in management and board structure to enhance corporate governance [5][7] - The company is preparing a Form S-1 registration statement to meet Nasdaq's governance and operational standards for relisting [7][8] - The Drugs Made in America Acquisition Corps, while aligned with PharmAGRI's strategy, operate independently to modernize U.S. pharmaceutical infrastructure [11][12]

Cannara Biotech Conference Summary Company Overview - **Company Name**: Cannara Biotech Inc. - **Stock Symbol**: LOVE (TSXV) - **Industry**: Canadian Cannabis - **Founded**: 2018 - **Headquarters**: Quebec, Canada - **Facilities**: Operates over 1.6 million square feet across two fully owned facilities in Quebec [2][5] Core Business and Market Position - Cannara Biotech is a vertically integrated cannabis company focused on producing premium-grade cannabis at scale, emphasizing profitability, innovation, and long-term value creation [2][4] - Currently the **seventh largest producer** in Canada by sales and **second largest** in Quebec, with a **12.8% market share** in Quebec, up from 9.7% a year ago [5][17] - Annualized production run rate is approximately **50,000 kilograms** (50 million grams) [5][6] Financial Performance - **Q3 2025**: Best quarterly financial results in the company's history - **Nine months of 2025**: - Net revenue: **$80 million** - Gross profit: **$32.7 million** - Gross margin: **41%**, with steady quarter-over-quarter increases [9][10] - Adjusted EBITDA: **$20.7 million** (26% of revenues) [10] - Net income: **$9.8 million**, a **53% increase** from the previous year [10] - **Cash Flow**: Generated **$17.2 million** in operating cash flow and **$12.3 million** in free cash flow in the first nine months of 2025 [11] Operational Highlights - Achieved a **26% increase** in capacity over the past year without additional capital costs [6][9] - Vertical integration allows full control over the cannabis supply chain, enhancing quality and efficiency [7][24] - Upcoming launch of a new vape category in Quebec, with **20% retail shelf space** already secured [8][17] Competitive Advantages - Strong operational platform with a focus on premium quality, scalable operations, and cost leadership [8][9] - Access to Quebec's low electricity rates of **$0.059 per kilowatt**, significantly lower than other provinces [26] - High barriers to entry in Quebec due to strict regulations on sales and marketing, allowing Cannara to thrive without heavy promotional activities [26][27] Strategic Initiatives - Plans for a **$10 million investment** in a new dedicated processing center to support growth and expand capacity to **100,000 kilograms** annually [16][24] - Focus on internal growth rather than external acquisitions, emphasizing operational discipline and quality [25][27] Market Trends and Outlook - The Canadian cannabis market is experiencing a shift, with a **41% surge** in estimated retail sales year-over-year, positioning Cannara as a leader in growth [16][17] - The company is well-prepared to meet unserved demand and capitalize on upcoming market opportunities, particularly in the vape segment [8][17] Conclusion - Cannara Biotech is positioned as a dominant player in the Canadian cannabis market, with a strong financial performance, operational efficiencies, and a clear growth strategy focused on quality and innovation [2][9][27]

Core Insights - Humana Inc. has received court approval to acquire The Villages Health assets for $68 million, aiming to enhance its senior-focused primary care platform and strengthen its Medicare Advantage membership base [1][2] Group 1: Acquisition Details - The acquisition is valued at $68 million and is expected to close in the fourth quarter of this year, allowing Humana to gain eight primary care and two specialty care centers [2] - This move indicates Humana's strategy to vertically integrate by combining insurance with care delivery to improve healthcare outcomes [2] Group 2: Challenges and Market Reaction - The former business model of The Villages Health was focused solely on Medicare Advantage patients and was linked to Medicare overpayments due to upcoding practices, raising concerns about the sustainability of this acquisition [3] - Following the announcement, Humana's shares fell over 12%, while competitors UnitedHealth Group and Centene Corporation saw their shares rise by 8.6% and 7.7%, respectively, reflecting investor sentiment towards the industry [5][7] Group 3: Financial Performance - CenterWell reported an adjusted operating income of $404 million in Q2 2025, a 2.5% increase year-over-year, although the operating cost ratio worsened to 92.7% [4][7] - Humana's shares have increased 7.6% year-to-date, contrasting with a 25.2% decline in the industry [6] Group 4: Valuation and Earnings Estimates - Humana trades at a forward price-to-earnings ratio of 18.97, higher than the industry average of 16.17, and carries a Value Score of A [9] - The Zacks Consensus Estimate for Humana's 2025 earnings is $16.99 per share, indicating a 4.8% increase from the previous year [10]

Core Viewpoint - Hydreight Technologies Inc. has entered into a strategic partnership with Perfect Scripts LLC, which includes acquiring a 5% membership interest in Perfect Scripts and establishing a 503B pharmacy in the U.S. [1][2] Company Overview - Hydreight Technologies Inc. operates a fully integrated mobile clinical network in North America, comprising over 2,500 nurses and 100 doctors, along with a pharmacy network across all 50 states [13][14]. - Perfect Scripts LLC is the parent company of PerfectRx LLC and PerfectionRx LLC, which operate pharmacies and provide pharmaceutical services [6][9]. Transaction Details - Hydreight will acquire a 5% membership interest in Perfect Scripts for 2,250,000 common shares, with a deemed price of CAD$2.30 per share or the lowest price permitted by the TSX Venture Exchange [2]. - The partnership will allow Hydreight to receive the lowest pricing for products sold by Perfect Scripts and grants the right to maintain and increase its membership interest up to 40% [2][3]. Financial Aspects - A cash finder's fee of $258,750 will be paid to a finder in connection with the transaction, representing 5% of the deemed value [3]. - The Hydreight Compensation Shares will vest in increments and are subject to a four-month statutory hold period under Canadian securities laws [4][5]. Strategic Implications - The partnership is expected to enhance Hydreight's pharmacy margins, secure a consistent supply chain, and provide vertical integration, which will strengthen its market position [6][8]. - The U.S. compounding pharmacy sector is projected to grow from $6.31 billion in 2024 to $10.76 billion by 2033, indicating significant market potential for Hydreight and Perfect Scripts [8]. Operational Capabilities - PerfectRx LLC operates a 30,000 sq ft licensed pharmacy and distribution center in Florida and can process over 150,000 prescriptions per day [7][10]. - The proprietary technology, PerfectOS, enables efficient digital prescription intake and real-time inventory management, enhancing operational efficiency [10][11]. Future Outlook - The partnership is viewed as a critical step in transforming access to modern healthcare and expanding Hydreight's product lineup [8]. - The VSDHOne platform, developed in partnership with Victory Square Technologies, aims to simplify the entry for companies into the online healthcare space, further supporting Hydreight's growth strategy [15].